Skip to content

Bristol-Myers Squibb Company Price, Chart & Factor Exposure

Free Data & Analytics Access

Next earnings: Thu, Feb 4, 2027, before the market opens · estimates and history

Bristol-Myers Squibb Company · E.BMY.MX · Mexico
Use symbol E.BMY.MX in our API & Excel add-in to retrieve this data ↓
1,184.00
(+0.03%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 50%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 54.83%

Bristol-Myers Squibb Company Forecast

Bristol-Myers Squibb Company short-term momentum is positive (up over 3 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 54.8% a year, a typical one-standard-deviation range is 1,093–1,275 over a week, 996.59–1,371 over a month and 534.80–1,833 over a year. (Signals as of 5 Nov 2026.)

Bristol-Myers Squibb Company Price Chart

MacroFinance.ai

Bristol-Myers Squibb Company Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Bristol-Myers Squibb Company
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Bristol-Myers Squibb Company
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Bristol-Myers Squibb Company
Signal
0
ⓘLatest reading of Signal.
Teal = supportive for Bristol-Myers Squibb Company, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Research on Bristol-Myers Squibb Company

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Bristol-Myers Squibb Company Trading Strategies

28 backtested tactical asset allocation strategies hold EEM (emerging markets), the closest tradable exposure to Bristol-Myers Squibb Company; 2 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

See all 28 strategies holding EEM →

Statistical Distribution of Returns

Plus

How Bristol-Myers Squibb Company’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Bristol-Myers Squibb Company behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Bristol-Myers Squibb Company (Mexico)

Bristol-Myers Squibb Company is a listed security in Mexico. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Bloomsbury Publishing Plc

Frequently asked questions

What is Bristol-Myers Squibb Company?
Bristol-Myers Squibb Company is a listed security in Mexico. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Bristol-Myers Squibb Company price?
The latest close is 1,184 (5 Nov 2026), +0.03% on the day. The price at the top of the page refreshes during the trading day.
Is Bristol-Myers Squibb Company in an uptrend?
As of 5 Nov 2026, short-term momentum is positive (3 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Bristol-Myers Squibb Company?
20-day realised volatility is 54.8% a year (5 Nov 2026), which implies a typical one-standard-deviation move of about 15.8% over a month and 7.7% over a week.
What factors affect Bristol-Myers Squibb Company?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Bristol-Myers Squibb Company, grouped as Quantitative Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Bristol-Myers Squibb Company?
28 backtested tactical asset allocation strategies trade Bristol-Myers Squibb Company through EEM; 2 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Bristol-Myers Squibb Company returns analysed?
The Statistical Distribution of Returns section shows the distribution of Bristol-Myers Squibb Company daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Bristol-Myers Squibb Company historical data?
In the Free historical data section of this page: the last 10 years of Bristol-Myers Squibb Company daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Bristol-Myers Squibb Company historical data (last 10 years)

Browse or instantly download the last 10 years of Bristol-Myers Squibb Company daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.BMY.MX&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-201130
2026-11-191115.2
2026-11-181128.24
2026-11-171128.24
2026-11-131149
2026-11-121149
2026-11-111149
2026-11-101140
2026-11-091150
2026-11-061190
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.